GSK plc (LSE/NYSE:GSK) has announced that the FDA has approved the Priorix measles, mumps and rubella (MMR) vaccine for individuals at least 12 months old.
Before the FDA approval, Merck & Co.’s M-M-R II was the only MMR vaccine currently FDA approved in the U.S. Merck also has a FDA-approved measles, mumps, rubella and varicella vaccine known as ProQuad.
Priorix is widely available throughout the world, having been licensed in more than 100 countries. More than 800 million doses have been distributed.
“We’re proud to make Priorix available in the U.S. for the first time, adding a choice for providers to help protect patients against these highly-contagious diseases and to further strengthen offerings in our pediatric vaccine portfolio,” said Judy Stewart, senior vice president and head of U.S. vaccines at GSK, in a news release.
Measles, mumps and rubella are highly contagious diseases.
In the U.S., measles surged in 2019, infecting at…